Phathom Pharmaceuticals Stock Analysis

Phathom Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.29. Phathom Pharmaceuticals had not issued any dividends in recent years. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Phathom Pharmaceuticals contact Terrie Curran at 877 742 8466 or learn more at https://www.phathompharma.com.

Phathom Pharmaceuticals Investment Alerts

Phathom Pharmaceuticals Upcoming and Recent Events

Phathom Largest EPS Surprises

View All Earnings Estimates

Phathom Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Phathom Stock Institutional Investors

Note, although Phathom Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Phathom Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 456.12 M.

Phathom Profitablity

Management Efficiency

Phathom Pharmaceuticals has return on total asset (ROA) of (0.4378) % which means that it has lost $0.4378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.89) %, meaning that it created substantial loss on money invested by shareholders. Phathom Pharmaceuticals' management efficiency ratios could be used to measure how well Phathom Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.38 in 2025, whereas Return On Tangible Assets are likely to drop (0.93) in 2025. At this time, Phathom Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 573.5 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 267.1 M in 2025.

Technical Drivers

As of the 26th of March, Phathom Pharmaceuticals holds the Variance of 33.34, risk adjusted performance of (0.03), and Coefficient Of Variation of (2,388). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phathom Pharmaceuticals, as well as the relationship between them.

Phathom Pharmaceuticals Price Movement Analysis

Phathom Pharmaceuticals Insider Trading Activities

Phathom Pharmaceuticals Outstanding Bonds

Phathom Pharmaceuticals Predictive Daily Indicators

Phathom Pharmaceuticals Corporate Filings

Phathom Pharmaceuticals Forecast Models

Phathom Pharmaceuticals' time-series forecasting models are one of many Phathom Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Phathom Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Phathom Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Phathom shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Phathom Pharmaceuticals. By using and applying Phathom Stock analysis, traders can create a robust methodology for identifying Phathom entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Phathom analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Phathom analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Phathom Pharmaceuticals stock analysis indicators help investors evaluate how Phathom Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Phathom Pharmaceuticals shares will generate the highest return on investment. By understating and applying Phathom Pharmaceuticals stock analysis, traders can identify Phathom Pharmaceuticals position entry and exit signals to maximize returns.

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.